GlassScriptPhysician profile
Gregory L Mauldin
NPI 1871673749
$221,226.36
in general payments reported to CMS, 2019-2025
60 companies · $3,457 in 2025
The $3,457 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166K · 2020: $33K · 2021: $5,245 · 2022: $3,870 · 2023: $6,021 · 2024: $3,002 · 2025: $3,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,597 · Consulting Fee: $2,590 · Education: $252 · Travel and Lodging: $42.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,596.69 |
| Consulting Fee | $2,590.00 |
| Education | $251.77 |
| Travel and Lodging | $42.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86,158.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $48,914.62 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $28,580.85 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $24,940.25 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Janssen Pharmaceuticals, INC | $16,083.23 | 2019-2022 | |
| Genzyme Corporation | $4,783.10 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,445.20 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Olympus Corporation of The Americas | $979.23 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $640.99 | 2022-2025 | Uptravi, Opsumit |
| Amgen INC. | $623.53 | 2021-2025 | Tezspire, Repatha, Otezla |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Grifols USA, LLC | $551.47 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $407.66 | 2020-2025 | Glassia |
| United Therapeutics Corporation | $350.12 | 2021-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $298.47 | 2020-2025 | Wakix |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.71 | 2023-2024 | |
| Pfizer INC. | $190.16 | 2019-2021 | |
| Allergan, INC. | $168.86 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $167.11 | 2019 | |
| Mallinckrodt Hospital Products INC. | $158.80 | 2021-2023 | Acthar |
| Galderma Laboratories, L.P. | $154.73 | 2020 | |
| Insmed, INC. | $147.32 | 2022-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $129.19 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $120.79 | 2021-2023 | |
| Baxter Healthcare | $120.30 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $102.85 | 2023-2024 | Inspire |
| Genentech USA, INC. | $86.87 | 2019 | |
| Resmed Corp | $75.72 | 2023-2024 | |
| Verona Pharma, INC. | $71.05 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $67.45 | 2019-2021 | |
| Viatris Specialty LLC | $60.69 | 2025 | Yupelri |
| Lilly USA, LLC | $57.52 | 2025 | Zepbound, Mounjaro |
| Intuitive Surgical, INC. | $50.45 | 2023 | Da Vinci Surgical System |
| Pulmonx Corporation | $47.40 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Mallinckrodt Enterprises LLC | $46.90 | 2019 | |
| Shire North American Group INC | $43.59 | 2019 | |
| Vifor Pharma, INC. | $42.93 | 2024 | Zemaira |
| Axsome Therapeutics, INC. | $31.88 | 2024-2025 | Sunosi |
| Circassia INC. | $30.45 | 2019 | |
| Gilead Sciences, INC. | $28.34 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $28.00 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $26.64 | 2023 | Opsumit |
| Celgene Corporation | $25.67 | 2025 | Opdivo |
| Ucb, INC. | $25.33 | 2025 | Bimzelx |
| Corcept Therapeutics | $25.25 | 2025 | Korlym |
| Csl Behring | $24.96 | 2024 | Hizentra |
| Janssen Biotech, INC. | $22.89 | 2025 | Tremfya |
| Xeris Pharmaceuticals, INC. | $22.74 | 2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $22.34 | 2024 | Nuzyra |
| Phadia US INC. | $20.86 | 2024 | Immunocap |
| Beta Bionics, INC. | $20.67 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| La Jolla Pharmaceutical Company | $18.81 | 2023 | Giapreza |
| Portola Pharmaceuticals, LLC | $18.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.18 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.07 | 2025 | Strensiq |
| Veran Medical Technologies, INC. | $16.54 | 2021 | |
| Merck Sharp & Dohme LLC | $14.66 | 2021 | |
| Sandoz INC. | $13.97 | 2025 | Treprostinil |
| Tactile Systems Technology INC | $13.68 | 2024 | Entre Plus, Flexitouch Plus |
| Itamar Medical INC | $10.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mauldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.